The DOI matches its Crossref record.
Greater Epoetin alfa Responsiveness Is Associated With Improved Survival in Hemodialysis Patients
Open accessAbstract
BACKGROUND AND OBJECTIVES: Among hemodialysis patients, achieved hemoglobin is associated with Epoetin alfa dose and erythropoietin responsiveness. A prospective erythropoietin responsiveness measure was developed and its association with mortality evaluated. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Data from 321 participants were used and randomized to the hematocrit normalization arm of the Normal Hematocrit Cardiac Trial. Subjects were to receive a 50% Epoetin alfa dose increase at randomization. The prospective erythropoietin responsiveness measure was defined as the ratio of weekly hematocrit change (over the 3 wk after randomization) per Epoetin alfa dose increase (1000 IU/wk) corresponding to the mandated 50% dose increase at randomization. The distribution of responsiveness was divided into quartiles. Over a 1-yr follow-up, Cox proportional hazard modeling evaluated associations between this responsiveness measure and mortality. RESULTS: Erythropoietin responsiveness values ranged from -2.1% to 2.4% per week per 1000 IU. Although subjects were similar across response quartiles, mortality ranged between 14% and 34% among subjects in the highest and lowest response quartiles (P = 0.0004), respectively. After adjusting for baseline prognostic indicators, highest versus lowest responsiveness was associated with a hazard ratio of 0.41 (95% confidence interval, 0.20 to 0.87). CONCLUSION: Lower erythropoietin responsiveness is a strong, independent predictor of mortality risk and should be considered when evaluating associations between clinical outcomes and potential prognostic indicators, such as Epoetin alfa dose and achieved hemoglobin values.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Erythropoietic response and outcomes in kidney disease and type 2 diabetes
Solomon, S. D., Uno, H., Lewis, E. F., Eckardt, K.-U., Lin, J., Burdmann, E. A., de Zeeuw, D., Ivanovich, P., Levey, A. S., Parfrey, P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005109 · Cited by 473
How the Target Hemoglobin of Renal Anemia Should Be?
Mimura, I., Tanaka, T., & Nangaku, M. (2015) · Nephron · doi:10.1159/000440849 · Cited by 416
KDIGO clinical practice guidelines for bisphosphonate treatment in chronic kidney disease
Woo, K. T., & Chan, C. M. (2011) · Kidney International · doi:10.1038/ki.2011.202 · Cited by 412
Macdougall, I. C., Bock, A. H., Carrera, F., Eckardt, K.-U., Gaillard, C., Van Wyck, D., Roubert, B., Nolen, J. G., Roger, S. D., & on behalf of the FIND-CKD Study Investigators (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu201 · Cited by 328
Icardi, A., Paoletti, E., De Nicola, L., Mazzaferro, S., Russo, R., & Cozzolino, M. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft021 · Cited by 158
Metadata
- Authors
- Kilpatrick, R. D., Critchlow, C. W., Fishbane, S., Besarab, A., Stehman-Breen, C., Krishnan, M., & Bradbury, B. D.
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2008-07
- Volume
- 3
- Issue
- 4
- Pages
- 1077-1083
- ISSN
- 1555-9041 (ISSN-L)
- OpenAlex
- W2170328739
- Cited by
- 206
- References
- 0
- FWCI
- 12.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Greater Epoetin alfa Responsiveness Is Associated With Improved Survival in Hemodialysis Patients. https://app.cochat.ai/papers/10.2215/cjn.04601007
- The paper
- Kilpatrick, R. D., Critchlow, C. W., Fishbane, S., Besarab, A., Stehman-Breen, C., Krishnan, M., & Bradbury, B. D. (2008). Greater Epoetin alfa Responsiveness Is Associated With Improved Survival in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.04601007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.